Literature DB >> 9096220

Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras.

I Sánchez-García1, D Martín-Zanca.   

Abstract

BCR-ABL is a chimaeric oncogene generated by translocation of sequences from the c-ABL protein-tyrosine kinase gene on chromosome 9 into the BCR gene on chromosome 22. Alternative chimeric proteins, p210(BCR-ABL) and p190(BCR-ABL), are produced that are characteristic of chronic myelogenous leukemia and acute lymphoblastic leukemia, respectively. Their role in the aetiology of human leukemia remains to be defined. We have previously shown that the tumorigenic effect of BCR-ABL oncogenes is mediated by Bcl-2. In addition to Bcl-2, is a protein essential for transformation by BCR-ABL. However, it is not known how Bcl-2 and Ras fit together in cell transformation by BCR-ABL. The data presented here establish that Bcl-2 is a downstream target gene of the Ras signalling pathway in cells transformed by BCR-ABL, and that constitutive Ras activation results in constitutive expression of the gene. Conversely, a truncated form of the BCR-ABL, which lacks a critical BCR region required for activation of the Ras signalling pathway, failed to induce Bcl-2 expression. These results indicate that BCR-ABL prevents apoptosis by inducing Bcl-2 through a signalling pathway involving Ras and links constitutive Ras activation and Bcl-2 gene regulation. Hence, these results further imply that Ras is involved in both mitogenic signals and survival signals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096220     DOI: 10.1006/jmbi.1996.0779

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  9 in total

Review 1.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Epithelial cells release proinflammatory cytokines and undergo c-Myc-induced apoptosis on exposure to filarial parasitic sheath protein-Bcl2 mediates rescue by activating c-H-Ras.

Authors:  B Krishnamoorthy; K Narayanan; S Miyamoto; A Balakrishnan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-09       Impact factor: 2.416

Review 3.  Src kinase signaling in leukaemia.

Authors:  Shaoguang Li
Journal:  Int J Biochem Cell Biol       Date:  2007-02-09       Impact factor: 5.085

4.  Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.

Authors:  Artur Slupianek; Grazyna Hoser; Ireneusz Majsterek; Agnieszka Bronisz; Maciej Malecki; Janusz Blasiak; Richard Fishel; Tomasz Skorski
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

5.  CRISPR/Cas9-Directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CML.

Authors:  Elena Vuelta; José L Ordoñez; David J Sanz; Sandra Ballesteros; Jesús M Hernández-Rivas; Lucía Méndez-Sánchez; Manuel Sánchez-Martín; Ignacio García-Tuñón
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

6.  A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis.

Authors:  Xinfeng Wang; Akhilesh Kumar Bajpai; Qingqing Gu; Arthur Centeno; Athena Starlard-Davenport; Pjotr Prins; Fuyi Xu; Lu Lu
Journal:  Leuk Res       Date:  2022-02-09       Impact factor: 3.715

Review 7.  Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.

Authors:  Christian Sillaber; Matthias Mayerhofer; Hermine Agis; Verena Sagaster; Christine Mannhalter; Wolfgang R Sperr; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

8.  The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.

Authors:  Ignacio García-Tuñón; María Hernández-Sánchez; José Luis Ordoñez; Veronica Alonso-Pérez; Miguel Álamo-Quijada; Rocio Benito; Carmen Guerrero; Jesús María Hernández-Rivas; Manuel Sánchez-Martín
Journal:  Oncotarget       Date:  2017-04-18

9.  Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia.

Authors:  Raquel Vinhas; Alexandra R Fernandes; Pedro V Baptista
Journal:  Mol Ther Nucleic Acids       Date:  2017-05-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.